-
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9. -
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:732-9. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction.
Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH.
Obstet Gynecol 2001;98:608-11. -
One-stage screening for pregnancy complications by color doppler assessment of the uterine arteries at 23 weeks' gestation.
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH.
Obstet Gynecol 2000;96:559-64.